nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—TEK—epilepsy syndrome	0.134	0.474	CbGaD
Nilotinib—CA4—epilepsy syndrome	0.0806	0.284	CbGaD
Nilotinib—CA3—Lacosamide—epilepsy syndrome	0.0402	0.0929	CbGbCtD
Nilotinib—ABCG2—epilepsy syndrome	0.0343	0.121	CbGaD
Nilotinib—CA3—Acetazolamide—epilepsy syndrome	0.0276	0.0639	CbGbCtD
Nilotinib—CA3—Zonisamide—epilepsy syndrome	0.0256	0.0591	CbGbCtD
Nilotinib—CYP2D6—epilepsy syndrome	0.02	0.0705	CbGaD
Nilotinib—CA14—Lacosamide—epilepsy syndrome	0.0167	0.0386	CbGbCtD
Nilotinib—CA6—Lacosamide—epilepsy syndrome	0.0158	0.0366	CbGbCtD
Nilotinib—ABCB1—epilepsy syndrome	0.0143	0.0503	CbGaD
Nilotinib—CA9—Lacosamide—epilepsy syndrome	0.0118	0.0274	CbGbCtD
Nilotinib—CA14—Acetazolamide—epilepsy syndrome	0.0115	0.0265	CbGbCtD
Nilotinib—CA1—Lacosamide—epilepsy syndrome	0.0111	0.0256	CbGbCtD
Nilotinib—CA6—Acetazolamide—epilepsy syndrome	0.0109	0.0252	CbGbCtD
Nilotinib—CA14—Zonisamide—epilepsy syndrome	0.0106	0.0246	CbGbCtD
Nilotinib—CA4—Lacosamide—epilepsy syndrome	0.0104	0.0241	CbGbCtD
Nilotinib—CA6—Zonisamide—epilepsy syndrome	0.0101	0.0233	CbGbCtD
Nilotinib—CA2—Lacosamide—epilepsy syndrome	0.00958	0.0222	CbGbCtD
Nilotinib—CA7—Acetazolamide—epilepsy syndrome	0.0095	0.022	CbGbCtD
Nilotinib—CA7—Zonisamide—epilepsy syndrome	0.00879	0.0203	CbGbCtD
Nilotinib—CA9—Acetazolamide—epilepsy syndrome	0.00815	0.0189	CbGbCtD
Nilotinib—CA12—Acetazolamide—epilepsy syndrome	0.00815	0.0189	CbGbCtD
Nilotinib—CA1—Acetazolamide—epilepsy syndrome	0.00763	0.0176	CbGbCtD
Nilotinib—CA12—Zonisamide—epilepsy syndrome	0.00754	0.0174	CbGbCtD
Nilotinib—CA9—Zonisamide—epilepsy syndrome	0.00754	0.0174	CbGbCtD
Nilotinib—CA6—Topiramate—epilepsy syndrome	0.00735	0.017	CbGbCtD
Nilotinib—CA4—Acetazolamide—epilepsy syndrome	0.00717	0.0166	CbGbCtD
Nilotinib—CA1—Zonisamide—epilepsy syndrome	0.00706	0.0163	CbGbCtD
Nilotinib—CA4—Zonisamide—epilepsy syndrome	0.00664	0.0153	CbGbCtD
Nilotinib—CA2—Acetazolamide—epilepsy syndrome	0.00659	0.0152	CbGbCtD
Nilotinib—CA7—Topiramate—epilepsy syndrome	0.00641	0.0148	CbGbCtD
Nilotinib—CA2—Zonisamide—epilepsy syndrome	0.0061	0.0141	CbGbCtD
Nilotinib—UGT1A1—Propofol—epilepsy syndrome	0.00596	0.0138	CbGbCtD
Nilotinib—CA9—Topiramate—epilepsy syndrome	0.0055	0.0127	CbGbCtD
Nilotinib—CA12—Topiramate—epilepsy syndrome	0.0055	0.0127	CbGbCtD
Nilotinib—CA1—Topiramate—epilepsy syndrome	0.00514	0.0119	CbGbCtD
Nilotinib—CA4—Topiramate—epilepsy syndrome	0.00484	0.0112	CbGbCtD
Nilotinib—CA2—Topiramate—epilepsy syndrome	0.00445	0.0103	CbGbCtD
Nilotinib—CYP2B6—Fosphenytoin—epilepsy syndrome	0.00384	0.00887	CbGbCtD
Nilotinib—CYP2B6—Clobazam—epilepsy syndrome	0.00333	0.00769	CbGbCtD
Nilotinib—CYP2C8—Trimethadione—epilepsy syndrome	0.00309	0.00715	CbGbCtD
Nilotinib—CYP2C8—Fosphenytoin—epilepsy syndrome	0.00291	0.00672	CbGbCtD
Nilotinib—CYP2B6—Carbamazepine—epilepsy syndrome	0.00276	0.00638	CbGbCtD
Nilotinib—CYP2B6—Primidone—epilepsy syndrome	0.00257	0.00595	CbGbCtD
Nilotinib—CYP2B6—Phenytoin—epilepsy syndrome	0.00247	0.00572	CbGbCtD
Nilotinib—ABCB1—Levetiracetam—epilepsy syndrome	0.00246	0.00569	CbGbCtD
Nilotinib—CYP2B6—Propofol—epilepsy syndrome	0.00231	0.00533	CbGbCtD
Nilotinib—CYP2B6—Phenobarbital—epilepsy syndrome	0.0022	0.0051	CbGbCtD
Nilotinib—CYP2B6—Midazolam—epilepsy syndrome	0.00217	0.00503	CbGbCtD
Nilotinib—CYP2C9—Trimethadione—epilepsy syndrome	0.00216	0.00499	CbGbCtD
Nilotinib—CYP2B6—Diazepam—epilepsy syndrome	0.00209	0.00483	CbGbCtD
Nilotinib—CYP2C8—Carbamazepine—epilepsy syndrome	0.00209	0.00483	CbGbCtD
Nilotinib—CYP2C9—Fosphenytoin—epilepsy syndrome	0.00203	0.00469	CbGbCtD
Nilotinib—CYP2C8—Primidone—epilepsy syndrome	0.00195	0.00451	CbGbCtD
Nilotinib—CYP2C8—Phenytoin—epilepsy syndrome	0.00187	0.00433	CbGbCtD
Nilotinib—CYP2C8—Propofol—epilepsy syndrome	0.00175	0.00404	CbGbCtD
Nilotinib—ABCB1—Clobazam—epilepsy syndrome	0.00171	0.00395	CbGbCtD
Nilotinib—CYP2C8—Phenobarbital—epilepsy syndrome	0.00167	0.00386	CbGbCtD
Nilotinib—CYP2B6—Valproic Acid—epilepsy syndrome	0.00165	0.00381	CbGbCtD
Nilotinib—ABCB1—Lamotrigine—epilepsy syndrome	0.00164	0.0038	CbGbCtD
Nilotinib—CYP2C8—Diazepam—epilepsy syndrome	0.00158	0.00366	CbGbCtD
Nilotinib—CYP2C9—Carbamazepine—epilepsy syndrome	0.00146	0.00337	CbGbCtD
Nilotinib—ABCB1—Carbamazepine—epilepsy syndrome	0.00141	0.00327	CbGbCtD
Nilotinib—CYP2C9—Primidone—epilepsy syndrome	0.00136	0.00314	CbGbCtD
Nilotinib—CYP3A4—Oxcarbazepine—epilepsy syndrome	0.00135	0.00312	CbGbCtD
Nilotinib—CYP2C9—Phenytoin—epilepsy syndrome	0.00131	0.00302	CbGbCtD
Nilotinib—ABCB1—Phenytoin—epilepsy syndrome	0.00127	0.00293	CbGbCtD
Nilotinib—CYP3A4—Trimethadione—epilepsy syndrome	0.00125	0.0029	CbGbCtD
Nilotinib—CYP3A4—Felbamate—epilepsy syndrome	0.00125	0.0029	CbGbCtD
Nilotinib—CYP2C8—Valproic Acid—epilepsy syndrome	0.00125	0.00289	CbGbCtD
Nilotinib—CYP2C9—Propofol—epilepsy syndrome	0.00122	0.00282	CbGbCtD
Nilotinib—CYP3A4—Fosphenytoin—epilepsy syndrome	0.00118	0.00273	CbGbCtD
Nilotinib—CYP2C9—Phenobarbital—epilepsy syndrome	0.00116	0.00269	CbGbCtD
Nilotinib—ABCB1—Phenobarbital—epilepsy syndrome	0.00113	0.00261	CbGbCtD
Nilotinib—ABCB1—Midazolam—epilepsy syndrome	0.00111	0.00258	CbGbCtD
Nilotinib—CYP2D6—Propofol—epilepsy syndrome	0.00111	0.00258	CbGbCtD
Nilotinib—CYP2C9—Diazepam—epilepsy syndrome	0.0011	0.00255	CbGbCtD
Nilotinib—ABCB1—Diazepam—epilepsy syndrome	0.00107	0.00248	CbGbCtD
Nilotinib—CYP3A4—Clonazepam—epilepsy syndrome	0.00107	0.00247	CbGbCtD
Nilotinib—CYP3A4—Clobazam—epilepsy syndrome	0.00102	0.00236	CbGbCtD
Nilotinib—CYP2C9—Valproic Acid—epilepsy syndrome	0.00087	0.00201	CbGbCtD
Nilotinib—CYP3A4—Rufinamide—epilepsy syndrome	0.000869	0.00201	CbGbCtD
Nilotinib—CYP3A4—Carbamazepine—epilepsy syndrome	0.000847	0.00196	CbGbCtD
Nilotinib—CYP3A4—Primidone—epilepsy syndrome	0.000791	0.00183	CbGbCtD
Nilotinib—CYP3A4—Phenytoin—epilepsy syndrome	0.00076	0.00176	CbGbCtD
Nilotinib—Ponatinib—TEK—epilepsy syndrome	0.000757	0.253	CrCbGaD
Nilotinib—CYP3A4—Propofol—epilepsy syndrome	0.000708	0.00164	CbGbCtD
Nilotinib—Ponatinib—RET—epilepsy syndrome	0.000704	0.235	CrCbGaD
Nilotinib—CYP3A4—Phenobarbital—epilepsy syndrome	0.000677	0.00157	CbGbCtD
Nilotinib—CYP3A4—Acetazolamide—epilepsy syndrome	0.000677	0.00157	CbGbCtD
Nilotinib—CYP3A4—Midazolam—epilepsy syndrome	0.000668	0.00154	CbGbCtD
Nilotinib—CYP3A4—Diazepam—epilepsy syndrome	0.000642	0.00148	CbGbCtD
Nilotinib—CYP3A4—Zonisamide—epilepsy syndrome	0.000626	0.00145	CbGbCtD
Nilotinib—CYP3A4—Valproic Acid—epilepsy syndrome	0.000506	0.00117	CbGbCtD
Nilotinib—CYP3A4—Topiramate—epilepsy syndrome	0.000457	0.00106	CbGbCtD
Nilotinib—Ponatinib—SRC—epilepsy syndrome	0.000393	0.131	CrCbGaD
Nilotinib—Ponatinib—KDR—epilepsy syndrome	0.00037	0.124	CrCbGaD
Nilotinib—MAPK14—brainstem—epilepsy syndrome	0.000283	0.00566	CbGeAlD
Nilotinib—ABL1—hindbrain—epilepsy syndrome	0.000282	0.00565	CbGeAlD
Nilotinib—EPHB2—central nervous system—epilepsy syndrome	0.000281	0.00562	CbGeAlD
Nilotinib—EPHA8—nervous system—epilepsy syndrome	0.00028	0.0056	CbGeAlD
Nilotinib—MAPK8—spinal cord—epilepsy syndrome	0.000277	0.00554	CbGeAlD
Nilotinib—MAPK11—head—epilepsy syndrome	0.000274	0.00549	CbGeAlD
Nilotinib—MAPK14—forebrain—epilepsy syndrome	0.000273	0.00546	CbGeAlD
Nilotinib—EPHA4—telencephalon—epilepsy syndrome	0.000272	0.00545	CbGeAlD
Nilotinib—CDC42BPB—head—epilepsy syndrome	0.000272	0.00545	CbGeAlD
Nilotinib—EPHA8—central nervous system—epilepsy syndrome	0.000269	0.00539	CbGeAlD
Nilotinib—CA3—telencephalon—epilepsy syndrome	0.000269	0.00538	CbGeAlD
Nilotinib—EPHA8—cerebellum—epilepsy syndrome	0.000263	0.00527	CbGeAlD
Nilotinib—MAPK11—nervous system—epilepsy syndrome	0.00026	0.00521	CbGeAlD
Nilotinib—CDC42BPB—nervous system—epilepsy syndrome	0.000258	0.00516	CbGeAlD
Nilotinib—EPHA3—head—epilepsy syndrome	0.000258	0.00516	CbGeAlD
Nilotinib—MAPK14—telencephalon—epilepsy syndrome	0.000251	0.00502	CbGeAlD
Nilotinib—MAPK11—central nervous system—epilepsy syndrome	0.00025	0.00501	CbGeAlD
Nilotinib—CDC42BPB—central nervous system—epilepsy syndrome	0.000248	0.00497	CbGeAlD
Nilotinib—MAPK8—head—epilepsy syndrome	0.000246	0.00493	CbGeAlD
Nilotinib—EPHA6—head—epilepsy syndrome	0.000246	0.00493	CbGeAlD
Nilotinib—MAPK11—cerebellum—epilepsy syndrome	0.000245	0.0049	CbGeAlD
Nilotinib—EPHA3—nervous system—epilepsy syndrome	0.000245	0.0049	CbGeAlD
Nilotinib—CA14—telencephalon—epilepsy syndrome	0.000244	0.00489	CbGeAlD
Nilotinib—CDC42BPB—cerebellum—epilepsy syndrome	0.000243	0.00486	CbGeAlD
Nilotinib—EPHB4—telencephalon—epilepsy syndrome	0.000238	0.00476	CbGeAlD
Nilotinib—EPHB6—forebrain—epilepsy syndrome	0.000237	0.00474	CbGeAlD
Nilotinib—BRAF—midbrain—epilepsy syndrome	0.000236	0.00472	CbGeAlD
Nilotinib—EPHA3—central nervous system—epilepsy syndrome	0.000236	0.00471	CbGeAlD
Nilotinib—HCK—medulla oblongata—epilepsy syndrome	0.000235	0.00471	CbGeAlD
Nilotinib—MAPK8—nervous system—epilepsy syndrome	0.000233	0.00467	CbGeAlD
Nilotinib—EPHA6—nervous system—epilepsy syndrome	0.000233	0.00467	CbGeAlD
Nilotinib—CA4—hindbrain—epilepsy syndrome	0.000232	0.00464	CbGeAlD
Nilotinib—EPHB3—spinal cord—epilepsy syndrome	0.000228	0.00457	CbGeAlD
Nilotinib—TEK—telencephalon—epilepsy syndrome	0.000228	0.00456	CbGeAlD
Nilotinib—LYN—head—epilepsy syndrome	0.000227	0.00455	CbGeAlD
Nilotinib—MAPK8—central nervous system—epilepsy syndrome	0.000225	0.0045	CbGeAlD
Nilotinib—EPHA6—central nervous system—epilepsy syndrome	0.000225	0.0045	CbGeAlD
Nilotinib—PDGFRA—forebrain—epilepsy syndrome	0.000224	0.00449	CbGeAlD
Nilotinib—EPHB2—brain—epilepsy syndrome	0.000223	0.00447	CbGeAlD
Nilotinib—MAPK8—cerebellum—epilepsy syndrome	0.00022	0.00439	CbGeAlD
Nilotinib—EPHB6—telencephalon—epilepsy syndrome	0.000218	0.00436	CbGeAlD
Nilotinib—LYN—nervous system—epilepsy syndrome	0.000215	0.00431	CbGeAlD
Nilotinib—HCK—midbrain—epilepsy syndrome	0.000215	0.00431	CbGeAlD
Nilotinib—EPHA4—medulla oblongata—epilepsy syndrome	0.000214	0.00428	CbGeAlD
Nilotinib—EPHA8—brain—epilepsy syndrome	0.000214	0.00428	CbGeAlD
Nilotinib—TIE1—head—epilepsy syndrome	0.000213	0.00427	CbGeAlD
Nilotinib—CA7—midbrain—epilepsy syndrome	0.000211	0.00421	CbGeAlD
Nilotinib—HCK—spinal cord—epilepsy syndrome	0.00021	0.0042	CbGeAlD
Nilotinib—MAP2K5—brainstem—epilepsy syndrome	0.00021	0.0042	CbGeAlD
Nilotinib—LYN—central nervous system—epilepsy syndrome	0.000207	0.00415	CbGeAlD
Nilotinib—CA12—forebrain—epilepsy syndrome	0.000207	0.00415	CbGeAlD
Nilotinib—PDGFRA—telencephalon—epilepsy syndrome	0.000206	0.00413	CbGeAlD
Nilotinib—EPHB3—head—epilepsy syndrome	0.000203	0.00406	CbGeAlD
Nilotinib—TIE1—nervous system—epilepsy syndrome	0.000202	0.00405	CbGeAlD
Nilotinib—MAPK11—brain—epilepsy syndrome	0.000199	0.00398	CbGeAlD
Nilotinib—CSF1R—forebrain—epilepsy syndrome	0.000198	0.00395	CbGeAlD
Nilotinib—CDC42BPB—brain—epilepsy syndrome	0.000197	0.00395	CbGeAlD
Nilotinib—TIE1—central nervous system—epilepsy syndrome	0.000195	0.0039	CbGeAlD
Nilotinib—Ponatinib—ABCG2—epilepsy syndrome	0.000193	0.0645	CrCbGaD
Nilotinib—EPHB3—nervous system—epilepsy syndrome	0.000192	0.00385	CbGeAlD
Nilotinib—CA2—hindbrain—epilepsy syndrome	0.000192	0.00385	CbGeAlD
Nilotinib—CA14—medulla oblongata—epilepsy syndrome	0.000192	0.00384	CbGeAlD
Nilotinib—CA12—telencephalon—epilepsy syndrome	0.00019	0.00381	CbGeAlD
Nilotinib—TIE1—cerebellum—epilepsy syndrome	0.00019	0.00381	CbGeAlD
Nilotinib—EPHB4—medulla oblongata—epilepsy syndrome	0.000187	0.00374	CbGeAlD
Nilotinib—EPHA3—brain—epilepsy syndrome	0.000187	0.00374	CbGeAlD
Nilotinib—HCK—head—epilepsy syndrome	0.000187	0.00373	CbGeAlD
Nilotinib—MAP2K5—telencephalon—epilepsy syndrome	0.000186	0.00373	CbGeAlD
Nilotinib—KIT—brainstem—epilepsy syndrome	0.000186	0.00372	CbGeAlD
Nilotinib—EPHB3—central nervous system—epilepsy syndrome	0.000185	0.00371	CbGeAlD
Nilotinib—BRAF—cerebellum—epilepsy syndrome	0.000183	0.00365	CbGeAlD
Nilotinib—CSF1R—telencephalon—epilepsy syndrome	0.000182	0.00364	CbGeAlD
Nilotinib—EPHB3—cerebellum—epilepsy syndrome	0.000181	0.00362	CbGeAlD
Nilotinib—TEK—medulla oblongata—epilepsy syndrome	0.000179	0.00358	CbGeAlD
Nilotinib—EPHA6—brain—epilepsy syndrome	0.000178	0.00357	CbGeAlD
Nilotinib—MAPK8—brain—epilepsy syndrome	0.000178	0.00357	CbGeAlD
Nilotinib—HCK—nervous system—epilepsy syndrome	0.000177	0.00354	CbGeAlD
Nilotinib—CA6—head—epilepsy syndrome	0.000177	0.00354	CbGeAlD
Nilotinib—MAPK14—spinal cord—epilepsy syndrome	0.000176	0.00352	CbGeAlD
Nilotinib—CA14—midbrain—epilepsy syndrome	0.000175	0.00351	CbGeAlD
Nilotinib—CA14—spinal cord—epilepsy syndrome	0.000171	0.00342	CbGeAlD
Nilotinib—EPHB6—medulla oblongata—epilepsy syndrome	0.000171	0.00342	CbGeAlD
Nilotinib—EPHB4—midbrain—epilepsy syndrome	0.000171	0.00342	CbGeAlD
Nilotinib—HCK—central nervous system—epilepsy syndrome	0.00017	0.00341	CbGeAlD
Nilotinib—EPHA4—head—epilepsy syndrome	0.00017	0.00339	CbGeAlD
Nilotinib—CA3—head—epilepsy syndrome	0.000167	0.00335	CbGeAlD
Nilotinib—EPHB4—spinal cord—epilepsy syndrome	0.000167	0.00334	CbGeAlD
Nilotinib—ABL2—cerebellum—epilepsy syndrome	0.000165	0.00331	CbGeAlD
Nilotinib—KIT—telencephalon—epilepsy syndrome	0.000165	0.0033	CbGeAlD
Nilotinib—LYN—brain—epilepsy syndrome	0.000165	0.00329	CbGeAlD
Nilotinib—CA1—forebrain—epilepsy syndrome	0.000164	0.00328	CbGeAlD
Nilotinib—TEK—midbrain—epilepsy syndrome	0.000164	0.00327	CbGeAlD
Nilotinib—CA7—cerebellum—epilepsy syndrome	0.000163	0.00326	CbGeAlD
Nilotinib—MAP4K1—brain—epilepsy syndrome	0.000162	0.00324	CbGeAlD
Nilotinib—ABL1—brainstem—epilepsy syndrome	0.000162	0.00324	CbGeAlD
Nilotinib—PDGFRB—telencephalon—epilepsy syndrome	0.000161	0.00322	CbGeAlD
Nilotinib—EPHA4—nervous system—epilepsy syndrome	0.000161	0.00322	CbGeAlD
Nilotinib—TEK—spinal cord—epilepsy syndrome	0.00016	0.00319	CbGeAlD
Nilotinib—CA3—nervous system—epilepsy syndrome	0.000159	0.00318	CbGeAlD
Nilotinib—MAPK14—head—epilepsy syndrome	0.000156	0.00313	CbGeAlD
Nilotinib—EPHB6—midbrain—epilepsy syndrome	0.000156	0.00313	CbGeAlD
Nilotinib—FGR—head—epilepsy syndrome	0.000156	0.00312	CbGeAlD
Nilotinib—EPHA4—central nervous system—epilepsy syndrome	0.000155	0.0031	CbGeAlD
Nilotinib—TIE1—brain—epilepsy syndrome	0.000155	0.0031	CbGeAlD
Nilotinib—CA3—central nervous system—epilepsy syndrome	0.000153	0.00306	CbGeAlD
Nilotinib—EPHB6—spinal cord—epilepsy syndrome	0.000153	0.00305	CbGeAlD
Nilotinib—EPHA4—cerebellum—epilepsy syndrome	0.000151	0.00303	CbGeAlD
Nilotinib—CA1—telencephalon—epilepsy syndrome	0.000151	0.00302	CbGeAlD
Nilotinib—BRAF—brain—epilepsy syndrome	0.000148	0.00297	CbGeAlD
Nilotinib—MAPK14—nervous system—epilepsy syndrome	0.000148	0.00297	CbGeAlD
Nilotinib—FGR—nervous system—epilepsy syndrome	0.000148	0.00295	CbGeAlD
Nilotinib—EPHB3—brain—epilepsy syndrome	0.000147	0.00294	CbGeAlD
Nilotinib—MAP2K5—medulla oblongata—epilepsy syndrome	0.000146	0.00293	CbGeAlD
Nilotinib—EPHA2—head—epilepsy syndrome	0.000145	0.00291	CbGeAlD
Nilotinib—PDGFRA—spinal cord—epilepsy syndrome	0.000145	0.00289	CbGeAlD
Nilotinib—ABL1—telencephalon—epilepsy syndrome	0.000144	0.00287	CbGeAlD
Nilotinib—CA9—cerebellum—epilepsy syndrome	0.000143	0.00286	CbGeAlD
Nilotinib—CSF1R—medulla oblongata—epilepsy syndrome	0.000143	0.00286	CbGeAlD
Nilotinib—MAPK14—central nervous system—epilepsy syndrome	0.000143	0.00286	CbGeAlD
Nilotinib—FGR—central nervous system—epilepsy syndrome	0.000142	0.00284	CbGeAlD
Nilotinib—TEK—head—epilepsy syndrome	0.000142	0.00284	CbGeAlD
Nilotinib—MAPK14—cerebellum—epilepsy syndrome	0.000139	0.00279	CbGeAlD
Nilotinib—EPHA2—nervous system—epilepsy syndrome	0.000138	0.00276	CbGeAlD
Nilotinib—CA14—cerebellum—epilepsy syndrome	0.000136	0.00272	CbGeAlD
Nilotinib—EPHB6—head—epilepsy syndrome	0.000136	0.00271	CbGeAlD
Nilotinib—HCK—brain—epilepsy syndrome	0.000135	0.00271	CbGeAlD
Nilotinib—TEK—nervous system—epilepsy syndrome	0.000134	0.00269	CbGeAlD
Nilotinib—ABL2—brain—epilepsy syndrome	0.000134	0.00269	CbGeAlD
Nilotinib—MAP2K5—midbrain—epilepsy syndrome	0.000134	0.00268	CbGeAlD
Nilotinib—CA4—brainstem—epilepsy syndrome	0.000133	0.00266	CbGeAlD
Nilotinib—EPHA2—central nervous system—epilepsy syndrome	0.000133	0.00266	CbGeAlD
Nilotinib—CA7—brain—epilepsy syndrome	0.000132	0.00265	CbGeAlD
Nilotinib—EPHB4—cerebellum—epilepsy syndrome	0.000132	0.00265	CbGeAlD
Nilotinib—CSF1R—midbrain—epilepsy syndrome	0.00013	0.00261	CbGeAlD
Nilotinib—MAP2K5—spinal cord—epilepsy syndrome	0.00013	0.00261	CbGeAlD
Nilotinib—KIT—medulla oblongata—epilepsy syndrome	0.00013	0.00259	CbGeAlD
Nilotinib—TEK—central nervous system—epilepsy syndrome	0.000129	0.00259	CbGeAlD
Nilotinib—EPHB6—nervous system—epilepsy syndrome	0.000129	0.00257	CbGeAlD
Nilotinib—PDGFRA—head—epilepsy syndrome	0.000128	0.00257	CbGeAlD
Nilotinib—CA4—forebrain—epilepsy syndrome	0.000128	0.00257	CbGeAlD
Nilotinib—CSF1R—spinal cord—epilepsy syndrome	0.000127	0.00255	CbGeAlD
Nilotinib—PDGFRB—medulla oblongata—epilepsy syndrome	0.000127	0.00253	CbGeAlD
Nilotinib—TEK—cerebellum—epilepsy syndrome	0.000127	0.00253	CbGeAlD
Nilotinib—EPHB6—central nervous system—epilepsy syndrome	0.000124	0.00248	CbGeAlD
Nilotinib—EPHA4—brain—epilepsy syndrome	0.000123	0.00246	CbGeAlD
Nilotinib—CYP2D6—hindbrain—epilepsy syndrome	0.000122	0.00244	CbGeAlD
Nilotinib—PDGFRA—nervous system—epilepsy syndrome	0.000122	0.00244	CbGeAlD
Nilotinib—CA3—brain—epilepsy syndrome	0.000121	0.00243	CbGeAlD
Nilotinib—EPHB6—cerebellum—epilepsy syndrome	0.000121	0.00242	CbGeAlD
Nilotinib—Imatinib—ABCG2—epilepsy syndrome	0.000119	0.0397	CrCbGaD
Nilotinib—CA12—head—epilepsy syndrome	0.000119	0.00237	CbGeAlD
Nilotinib—KIT—midbrain—epilepsy syndrome	0.000118	0.00237	CbGeAlD
Nilotinib—CA4—telencephalon—epilepsy syndrome	0.000118	0.00236	CbGeAlD
Nilotinib—PDGFRA—central nervous system—epilepsy syndrome	0.000117	0.00235	CbGeAlD
Nilotinib—MAP2K5—head—epilepsy syndrome	0.000116	0.00232	CbGeAlD
Nilotinib—PDGFRB—midbrain—epilepsy syndrome	0.000116	0.00232	CbGeAlD
Nilotinib—KIT—spinal cord—epilepsy syndrome	0.000116	0.00231	CbGeAlD
Nilotinib—PDGFRA—cerebellum—epilepsy syndrome	0.000115	0.00229	CbGeAlD
Nilotinib—MAPK14—brain—epilepsy syndrome	0.000113	0.00227	CbGeAlD
Nilotinib—CSF1R—head—epilepsy syndrome	0.000113	0.00226	CbGeAlD
Nilotinib—PDGFRB—spinal cord—epilepsy syndrome	0.000113	0.00226	CbGeAlD
Nilotinib—ABL1—medulla oblongata—epilepsy syndrome	0.000113	0.00226	CbGeAlD
Nilotinib—FGR—brain—epilepsy syndrome	0.000113	0.00226	CbGeAlD
Nilotinib—Ponatinib—CYP2D6—epilepsy syndrome	0.000113	0.0376	CrCbGaD
Nilotinib—CA12—nervous system—epilepsy syndrome	0.000112	0.00225	CbGeAlD
Nilotinib—CA14—brain—epilepsy syndrome	0.00011	0.00221	CbGeAlD
Nilotinib—CA2—brainstem—epilepsy syndrome	0.00011	0.00221	CbGeAlD
Nilotinib—MAP2K5—nervous system—epilepsy syndrome	0.00011	0.0022	CbGeAlD
Nilotinib—CA12—central nervous system—epilepsy syndrome	0.000108	0.00217	CbGeAlD
Nilotinib—EPHB4—brain—epilepsy syndrome	0.000107	0.00215	CbGeAlD
Nilotinib—CSF1R—nervous system—epilepsy syndrome	0.000107	0.00215	CbGeAlD
Nilotinib—CA2—forebrain—epilepsy syndrome	0.000106	0.00213	CbGeAlD
Nilotinib—MAP2K5—central nervous system—epilepsy syndrome	0.000106	0.00212	CbGeAlD
Nilotinib—CA1—spinal cord—epilepsy syndrome	0.000106	0.00212	CbGeAlD
Nilotinib—EPHA2—brain—epilepsy syndrome	0.000105	0.00211	CbGeAlD
Nilotinib—MAP2K5—cerebellum—epilepsy syndrome	0.000103	0.00207	CbGeAlD
Nilotinib—CSF1R—central nervous system—epilepsy syndrome	0.000103	0.00207	CbGeAlD
Nilotinib—ABL1—midbrain—epilepsy syndrome	0.000103	0.00206	CbGeAlD
Nilotinib—TEK—brain—epilepsy syndrome	0.000103	0.00206	CbGeAlD
Nilotinib—KIT—head—epilepsy syndrome	0.000103	0.00206	CbGeAlD
Nilotinib—CSF1R—cerebellum—epilepsy syndrome	0.000101	0.00202	CbGeAlD
Nilotinib—ABL1—spinal cord—epilepsy syndrome	0.000101	0.00201	CbGeAlD
Nilotinib—PDGFRB—head—epilepsy syndrome	0.0001	0.00201	CbGeAlD
Nilotinib—EPHB6—brain—epilepsy syndrome	9.82e-05	0.00197	CbGeAlD
Nilotinib—CA2—telencephalon—epilepsy syndrome	9.78e-05	0.00196	CbGeAlD
Nilotinib—KIT—nervous system—epilepsy syndrome	9.74e-05	0.00195	CbGeAlD
Nilotinib—PDGFRB—nervous system—epilepsy syndrome	9.51e-05	0.0019	CbGeAlD
Nilotinib—CA1—head—epilepsy syndrome	9.39e-05	0.00188	CbGeAlD
Nilotinib—KIT—central nervous system—epilepsy syndrome	9.38e-05	0.00188	CbGeAlD
Nilotinib—Imatinib—CYP2C19—epilepsy syndrome	9.35e-05	0.0312	CrCbGaD
Nilotinib—PDGFRA—brain—epilepsy syndrome	9.31e-05	0.00186	CbGeAlD
Nilotinib—CA4—medulla oblongata—epilepsy syndrome	9.27e-05	0.00185	CbGeAlD
Nilotinib—KIT—cerebellum—epilepsy syndrome	9.16e-05	0.00183	CbGeAlD
Nilotinib—PDGFRB—central nervous system—epilepsy syndrome	9.16e-05	0.00183	CbGeAlD
Nilotinib—ABCG2—telencephalon—epilepsy syndrome	9.06e-05	0.00181	CbGeAlD
Nilotinib—PDGFRB—cerebellum—epilepsy syndrome	8.95e-05	0.00179	CbGeAlD
Nilotinib—ABL1—head—epilepsy syndrome	8.94e-05	0.00179	CbGeAlD
Nilotinib—CA1—nervous system—epilepsy syndrome	8.91e-05	0.00178	CbGeAlD
Nilotinib—CA12—brain—epilepsy syndrome	8.59e-05	0.00172	CbGeAlD
Nilotinib—CA1—central nervous system—epilepsy syndrome	8.58e-05	0.00172	CbGeAlD
Nilotinib—ABL1—nervous system—epilepsy syndrome	8.48e-05	0.0017	CbGeAlD
Nilotinib—CA4—midbrain—epilepsy syndrome	8.47e-05	0.00169	CbGeAlD
Nilotinib—MAP2K5—brain—epilepsy syndrome	8.4e-05	0.00168	CbGeAlD
Nilotinib—CA4—spinal cord—epilepsy syndrome	8.26e-05	0.00165	CbGeAlD
Nilotinib—CSF1R—brain—epilepsy syndrome	8.2e-05	0.00164	CbGeAlD
Nilotinib—ABL1—central nervous system—epilepsy syndrome	8.16e-05	0.00163	CbGeAlD
Nilotinib—Ponatinib—ABCB1—epilepsy syndrome	8.04e-05	0.0269	CrCbGaD
Nilotinib—ABL1—cerebellum—epilepsy syndrome	7.98e-05	0.0016	CbGeAlD
Nilotinib—CA2—medulla oblongata—epilepsy syndrome	7.68e-05	0.00154	CbGeAlD
Nilotinib—KIT—brain—epilepsy syndrome	7.44e-05	0.00149	CbGeAlD
Nilotinib—CA4—head—epilepsy syndrome	7.34e-05	0.00147	CbGeAlD
Nilotinib—PDGFRB—brain—epilepsy syndrome	7.27e-05	0.00146	CbGeAlD
Nilotinib—ABCG2—medulla oblongata—epilepsy syndrome	7.12e-05	0.00142	CbGeAlD
Nilotinib—CA2—midbrain—epilepsy syndrome	7.02e-05	0.00141	CbGeAlD
Nilotinib—CYP2D6—brainstem—epilepsy syndrome	6.99e-05	0.0014	CbGeAlD
Nilotinib—CA4—nervous system—epilepsy syndrome	6.96e-05	0.00139	CbGeAlD
Nilotinib—Imatinib—CYP2D6—epilepsy syndrome	6.93e-05	0.0232	CrCbGaD
Nilotinib—CA2—spinal cord—epilepsy syndrome	6.85e-05	0.00137	CbGeAlD
Nilotinib—CA1—brain—epilepsy syndrome	6.81e-05	0.00136	CbGeAlD
Nilotinib—CYP2D6—forebrain—epilepsy syndrome	6.75e-05	0.00135	CbGeAlD
Nilotinib—CA4—central nervous system—epilepsy syndrome	6.7e-05	0.00134	CbGeAlD
Nilotinib—CA4—cerebellum—epilepsy syndrome	6.55e-05	0.00131	CbGeAlD
Nilotinib—ABCG2—midbrain—epilepsy syndrome	6.5e-05	0.0013	CbGeAlD
Nilotinib—ABL1—brain—epilepsy syndrome	6.48e-05	0.0013	CbGeAlD
Nilotinib—ABCG2—spinal cord—epilepsy syndrome	6.34e-05	0.00127	CbGeAlD
Nilotinib—CYP2D6—telencephalon—epilepsy syndrome	6.21e-05	0.00124	CbGeAlD
Nilotinib—CA2—head—epilepsy syndrome	6.09e-05	0.00122	CbGeAlD
Nilotinib—CA2—nervous system—epilepsy syndrome	5.77e-05	0.00116	CbGeAlD
Nilotinib—CA2—central nervous system—epilepsy syndrome	5.56e-05	0.00111	CbGeAlD
Nilotinib—CA2—cerebellum—epilepsy syndrome	5.43e-05	0.00109	CbGeAlD
Nilotinib—CA4—brain—epilepsy syndrome	5.32e-05	0.00106	CbGeAlD
Nilotinib—CYP2B6—head—epilepsy syndrome	5.2e-05	0.00104	CbGeAlD
Nilotinib—Imatinib—ALB—epilepsy syndrome	5.19e-05	0.0173	CrCbGaD
Nilotinib—ABCG2—cerebellum—epilepsy syndrome	5.03e-05	0.00101	CbGeAlD
Nilotinib—Imatinib—ABCB1—epilepsy syndrome	4.95e-05	0.0165	CrCbGaD
Nilotinib—CYP2B6—nervous system—epilepsy syndrome	4.93e-05	0.000987	CbGeAlD
Nilotinib—ABCB1—forebrain—epilepsy syndrome	4.86e-05	0.000972	CbGeAlD
Nilotinib—CYP2B6—central nervous system—epilepsy syndrome	4.75e-05	0.00095	CbGeAlD
Nilotinib—ABCB1—telencephalon—epilepsy syndrome	4.47e-05	0.000894	CbGeAlD
Nilotinib—CA2—brain—epilepsy syndrome	4.41e-05	0.000883	CbGeAlD
Nilotinib—CYP2C8—brain—epilepsy syndrome	4.2e-05	0.000841	CbGeAlD
Nilotinib—ABCG2—brain—epilepsy syndrome	4.09e-05	0.000818	CbGeAlD
Nilotinib—CYP2D6—head—epilepsy syndrome	3.87e-05	0.000774	CbGeAlD
Nilotinib—CYP2B6—brain—epilepsy syndrome	3.77e-05	0.000754	CbGeAlD
Nilotinib—CYP3A4—nervous system—epilepsy syndrome	3.72e-05	0.000745	CbGeAlD
Nilotinib—CYP2D6—nervous system—epilepsy syndrome	3.66e-05	0.000733	CbGeAlD
Nilotinib—CYP3A4—central nervous system—epilepsy syndrome	3.59e-05	0.000718	CbGeAlD
Nilotinib—CYP2D6—central nervous system—epilepsy syndrome	3.53e-05	0.000706	CbGeAlD
Nilotinib—ABCB1—medulla oblongata—epilepsy syndrome	3.51e-05	0.000702	CbGeAlD
Nilotinib—CYP2D6—cerebellum—epilepsy syndrome	3.45e-05	0.00069	CbGeAlD
Nilotinib—ABCB1—midbrain—epilepsy syndrome	3.21e-05	0.000642	CbGeAlD
Nilotinib—ABCB1—spinal cord—epilepsy syndrome	3.13e-05	0.000626	CbGeAlD
Nilotinib—CYP2D6—brain—epilepsy syndrome	2.8e-05	0.000561	CbGeAlD
Nilotinib—ABCB1—head—epilepsy syndrome	2.78e-05	0.000556	CbGeAlD
Nilotinib—ABCB1—nervous system—epilepsy syndrome	2.64e-05	0.000528	CbGeAlD
Nilotinib—ABCB1—central nervous system—epilepsy syndrome	2.54e-05	0.000508	CbGeAlD
Nilotinib—ABCB1—cerebellum—epilepsy syndrome	2.48e-05	0.000496	CbGeAlD
Nilotinib—Dermatitis—Diazepam—epilepsy syndrome	2.05e-05	0.000167	CcSEcCtD
Nilotinib—Visual impairment—Topiramate—epilepsy syndrome	2.05e-05	0.000167	CcSEcCtD
Nilotinib—Chest pain—Pregabalin—epilepsy syndrome	2.04e-05	0.000166	CcSEcCtD
Nilotinib—Myalgia—Pregabalin—epilepsy syndrome	2.04e-05	0.000166	CcSEcCtD
Nilotinib—Arthralgia—Pregabalin—epilepsy syndrome	2.04e-05	0.000166	CcSEcCtD
Nilotinib—Ill-defined disorder—Gabapentin—epilepsy syndrome	2.04e-05	0.000166	CcSEcCtD
Nilotinib—Dizziness—Zonisamide—epilepsy syndrome	2.04e-05	0.000166	CcSEcCtD
Nilotinib—Headache—Diazepam—epilepsy syndrome	2.04e-05	0.000166	CcSEcCtD
Nilotinib—Anxiety—Pregabalin—epilepsy syndrome	2.03e-05	0.000165	CcSEcCtD
Nilotinib—Diarrhoea—Clonazepam—epilepsy syndrome	2.03e-05	0.000165	CcSEcCtD
Nilotinib—Anaemia—Gabapentin—epilepsy syndrome	2.03e-05	0.000165	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Pregabalin—epilepsy syndrome	2.02e-05	0.000165	CcSEcCtD
Nilotinib—Hypotension—Valproic Acid—epilepsy syndrome	2.02e-05	0.000165	CcSEcCtD
Nilotinib—Asthenia—Carbamazepine—epilepsy syndrome	2.02e-05	0.000164	CcSEcCtD
Nilotinib—Diarrhoea—Phenytoin—epilepsy syndrome	2.02e-05	0.000164	CcSEcCtD
Nilotinib—ABCB1—brain—epilepsy syndrome	2.02e-05	0.000403	CbGeAlD
Nilotinib—Discomfort—Pregabalin—epilepsy syndrome	2.01e-05	0.000164	CcSEcCtD
Nilotinib—Nausea—Fosphenytoin—epilepsy syndrome	2.01e-05	0.000164	CcSEcCtD
Nilotinib—Diarrhoea—Oxcarbazepine—epilepsy syndrome	2.01e-05	0.000163	CcSEcCtD
Nilotinib—Erythema multiforme—Topiramate—epilepsy syndrome	2.01e-05	0.000163	CcSEcCtD
Nilotinib—Hypersensitivity—Lamotrigine—epilepsy syndrome	2e-05	0.000163	CcSEcCtD
Nilotinib—Vomiting—Felbamate—epilepsy syndrome	2e-05	0.000163	CcSEcCtD
Nilotinib—Dry mouth—Pregabalin—epilepsy syndrome	1.99e-05	0.000162	CcSEcCtD
Nilotinib—Pruritus—Carbamazepine—epilepsy syndrome	1.99e-05	0.000162	CcSEcCtD
Nilotinib—Rash—Felbamate—epilepsy syndrome	1.98e-05	0.000162	CcSEcCtD
Nilotinib—Eye disorder—Topiramate—epilepsy syndrome	1.98e-05	0.000162	CcSEcCtD
Nilotinib—Dermatitis—Felbamate—epilepsy syndrome	1.98e-05	0.000161	CcSEcCtD
Nilotinib—Malaise—Gabapentin—epilepsy syndrome	1.98e-05	0.000161	CcSEcCtD
Nilotinib—Tinnitus—Topiramate—epilepsy syndrome	1.98e-05	0.000161	CcSEcCtD
Nilotinib—Vertigo—Gabapentin—epilepsy syndrome	1.97e-05	0.000161	CcSEcCtD
Nilotinib—Headache—Felbamate—epilepsy syndrome	1.97e-05	0.000161	CcSEcCtD
Nilotinib—Confusional state—Pregabalin—epilepsy syndrome	1.97e-05	0.00016	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Valproic Acid—epilepsy syndrome	1.97e-05	0.00016	CcSEcCtD
Nilotinib—Flushing—Topiramate—epilepsy syndrome	1.97e-05	0.00016	CcSEcCtD
Nilotinib—Cardiac disorder—Topiramate—epilepsy syndrome	1.97e-05	0.00016	CcSEcCtD
Nilotinib—Syncope—Gabapentin—epilepsy syndrome	1.97e-05	0.00016	CcSEcCtD
Nilotinib—Leukopenia—Gabapentin—epilepsy syndrome	1.97e-05	0.00016	CcSEcCtD
Nilotinib—Dizziness—Clonazepam—epilepsy syndrome	1.96e-05	0.00016	CcSEcCtD
Nilotinib—Nausea—Vigabatrin—epilepsy syndrome	1.96e-05	0.00016	CcSEcCtD
Nilotinib—Vomiting—Zonisamide—epilepsy syndrome	1.96e-05	0.00016	CcSEcCtD
Nilotinib—Insomnia—Valproic Acid—epilepsy syndrome	1.96e-05	0.000159	CcSEcCtD
Nilotinib—Oedema—Pregabalin—epilepsy syndrome	1.95e-05	0.000159	CcSEcCtD
Nilotinib—Asthenia—Lamotrigine—epilepsy syndrome	1.95e-05	0.000159	CcSEcCtD
Nilotinib—Dizziness—Phenytoin—epilepsy syndrome	1.95e-05	0.000159	CcSEcCtD
Nilotinib—Rash—Zonisamide—epilepsy syndrome	1.94e-05	0.000158	CcSEcCtD
Nilotinib—Infection—Pregabalin—epilepsy syndrome	1.94e-05	0.000158	CcSEcCtD
Nilotinib—Paraesthesia—Valproic Acid—epilepsy syndrome	1.94e-05	0.000158	CcSEcCtD
Nilotinib—Palpitations—Gabapentin—epilepsy syndrome	1.94e-05	0.000158	CcSEcCtD
Nilotinib—Dermatitis—Zonisamide—epilepsy syndrome	1.94e-05	0.000158	CcSEcCtD
Nilotinib—Dizziness—Oxcarbazepine—epilepsy syndrome	1.94e-05	0.000158	CcSEcCtD
Nilotinib—Nausea—Diazepam—epilepsy syndrome	1.93e-05	0.000157	CcSEcCtD
Nilotinib—Loss of consciousness—Gabapentin—epilepsy syndrome	1.93e-05	0.000157	CcSEcCtD
Nilotinib—Headache—Zonisamide—epilepsy syndrome	1.93e-05	0.000157	CcSEcCtD
Nilotinib—Dyspnoea—Valproic Acid—epilepsy syndrome	1.93e-05	0.000157	CcSEcCtD
Nilotinib—Diarrhoea—Carbamazepine—epilepsy syndrome	1.93e-05	0.000157	CcSEcCtD
Nilotinib—Angiopathy—Topiramate—epilepsy syndrome	1.93e-05	0.000157	CcSEcCtD
Nilotinib—Pruritus—Lamotrigine—epilepsy syndrome	1.93e-05	0.000157	CcSEcCtD
Nilotinib—Shock—Pregabalin—epilepsy syndrome	1.92e-05	0.000157	CcSEcCtD
Nilotinib—Immune system disorder—Topiramate—epilepsy syndrome	1.92e-05	0.000156	CcSEcCtD
Nilotinib—Nervous system disorder—Pregabalin—epilepsy syndrome	1.92e-05	0.000156	CcSEcCtD
Nilotinib—Cough—Gabapentin—epilepsy syndrome	1.92e-05	0.000156	CcSEcCtD
Nilotinib—Thrombocytopenia—Pregabalin—epilepsy syndrome	1.91e-05	0.000156	CcSEcCtD
Nilotinib—Mediastinal disorder—Topiramate—epilepsy syndrome	1.91e-05	0.000156	CcSEcCtD
Nilotinib—Tachycardia—Pregabalin—epilepsy syndrome	1.91e-05	0.000155	CcSEcCtD
Nilotinib—Chills—Topiramate—epilepsy syndrome	1.9e-05	0.000155	CcSEcCtD
Nilotinib—Dyspepsia—Valproic Acid—epilepsy syndrome	1.9e-05	0.000155	CcSEcCtD
Nilotinib—Skin disorder—Pregabalin—epilepsy syndrome	1.9e-05	0.000155	CcSEcCtD
Nilotinib—Hypertension—Gabapentin—epilepsy syndrome	1.9e-05	0.000154	CcSEcCtD
Nilotinib—Hyperhidrosis—Pregabalin—epilepsy syndrome	1.89e-05	0.000154	CcSEcCtD
Nilotinib—Vomiting—Clonazepam—epilepsy syndrome	1.89e-05	0.000154	CcSEcCtD
Nilotinib—Decreased appetite—Valproic Acid—epilepsy syndrome	1.88e-05	0.000153	CcSEcCtD
Nilotinib—Alopecia—Topiramate—epilepsy syndrome	1.88e-05	0.000153	CcSEcCtD
Nilotinib—Vomiting—Phenytoin—epilepsy syndrome	1.88e-05	0.000153	CcSEcCtD
Nilotinib—Rash—Clonazepam—epilepsy syndrome	1.87e-05	0.000152	CcSEcCtD
Nilotinib—Dermatitis—Clonazepam—epilepsy syndrome	1.87e-05	0.000152	CcSEcCtD
Nilotinib—Chest pain—Gabapentin—epilepsy syndrome	1.87e-05	0.000152	CcSEcCtD
Nilotinib—Arthralgia—Gabapentin—epilepsy syndrome	1.87e-05	0.000152	CcSEcCtD
Nilotinib—Myalgia—Gabapentin—epilepsy syndrome	1.87e-05	0.000152	CcSEcCtD
Nilotinib—Nausea—Felbamate—epilepsy syndrome	1.87e-05	0.000152	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	1.87e-05	0.000152	CcSEcCtD
Nilotinib—Vomiting—Oxcarbazepine—epilepsy syndrome	1.87e-05	0.000152	CcSEcCtD
Nilotinib—Fatigue—Valproic Acid—epilepsy syndrome	1.86e-05	0.000152	CcSEcCtD
Nilotinib—Anxiety—Gabapentin—epilepsy syndrome	1.86e-05	0.000152	CcSEcCtD
Nilotinib—Anorexia—Pregabalin—epilepsy syndrome	1.86e-05	0.000152	CcSEcCtD
Nilotinib—Dizziness—Carbamazepine—epilepsy syndrome	1.86e-05	0.000152	CcSEcCtD
Nilotinib—Diarrhoea—Lamotrigine—epilepsy syndrome	1.86e-05	0.000152	CcSEcCtD
Nilotinib—Headache—Clonazepam—epilepsy syndrome	1.86e-05	0.000151	CcSEcCtD
Nilotinib—Rash—Phenytoin—epilepsy syndrome	1.86e-05	0.000151	CcSEcCtD
Nilotinib—Mental disorder—Topiramate—epilepsy syndrome	1.86e-05	0.000151	CcSEcCtD
Nilotinib—Dermatitis—Phenytoin—epilepsy syndrome	1.86e-05	0.000151	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—epilepsy syndrome	1.86e-05	0.000151	CcSEcCtD
Nilotinib—Rash—Oxcarbazepine—epilepsy syndrome	1.85e-05	0.000151	CcSEcCtD
Nilotinib—Pain—Valproic Acid—epilepsy syndrome	1.85e-05	0.000151	CcSEcCtD
Nilotinib—Constipation—Valproic Acid—epilepsy syndrome	1.85e-05	0.000151	CcSEcCtD
Nilotinib—Dermatitis—Oxcarbazepine—epilepsy syndrome	1.85e-05	0.00015	CcSEcCtD
Nilotinib—Headache—Phenytoin—epilepsy syndrome	1.85e-05	0.00015	CcSEcCtD
Nilotinib—Erythema—Topiramate—epilepsy syndrome	1.85e-05	0.00015	CcSEcCtD
Nilotinib—Malnutrition—Topiramate—epilepsy syndrome	1.85e-05	0.00015	CcSEcCtD
Nilotinib—Discomfort—Gabapentin—epilepsy syndrome	1.85e-05	0.00015	CcSEcCtD
Nilotinib—Headache—Oxcarbazepine—epilepsy syndrome	1.84e-05	0.00015	CcSEcCtD
Nilotinib—Nausea—Zonisamide—epilepsy syndrome	1.83e-05	0.000149	CcSEcCtD
Nilotinib—Dry mouth—Gabapentin—epilepsy syndrome	1.83e-05	0.000149	CcSEcCtD
Nilotinib—Hypotension—Pregabalin—epilepsy syndrome	1.83e-05	0.000149	CcSEcCtD
Nilotinib—Flatulence—Topiramate—epilepsy syndrome	1.82e-05	0.000148	CcSEcCtD
Nilotinib—Dysgeusia—Topiramate—epilepsy syndrome	1.81e-05	0.000147	CcSEcCtD
Nilotinib—Confusional state—Gabapentin—epilepsy syndrome	1.81e-05	0.000147	CcSEcCtD
Nilotinib—Dizziness—Lamotrigine—epilepsy syndrome	1.8e-05	0.000147	CcSEcCtD
Nilotinib—Oedema—Gabapentin—epilepsy syndrome	1.79e-05	0.000146	CcSEcCtD
Nilotinib—Vomiting—Carbamazepine—epilepsy syndrome	1.79e-05	0.000146	CcSEcCtD
Nilotinib—Back pain—Topiramate—epilepsy syndrome	1.79e-05	0.000146	CcSEcCtD
Nilotinib—Feeling abnormal—Valproic Acid—epilepsy syndrome	1.78e-05	0.000145	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Pregabalin—epilepsy syndrome	1.78e-05	0.000145	CcSEcCtD
Nilotinib—Infection—Gabapentin—epilepsy syndrome	1.78e-05	0.000145	CcSEcCtD
Nilotinib—Muscle spasms—Topiramate—epilepsy syndrome	1.78e-05	0.000145	CcSEcCtD
Nilotinib—Rash—Carbamazepine—epilepsy syndrome	1.78e-05	0.000145	CcSEcCtD
Nilotinib—Dermatitis—Carbamazepine—epilepsy syndrome	1.77e-05	0.000144	CcSEcCtD
Nilotinib—Gastrointestinal pain—Valproic Acid—epilepsy syndrome	1.77e-05	0.000144	CcSEcCtD
Nilotinib—Insomnia—Pregabalin—epilepsy syndrome	1.77e-05	0.000144	CcSEcCtD
Nilotinib—Nausea—Clonazepam—epilepsy syndrome	1.76e-05	0.000144	CcSEcCtD
Nilotinib—Headache—Carbamazepine—epilepsy syndrome	1.76e-05	0.000144	CcSEcCtD
Nilotinib—Shock—Gabapentin—epilepsy syndrome	1.76e-05	0.000144	CcSEcCtD
Nilotinib—Nervous system disorder—Gabapentin—epilepsy syndrome	1.76e-05	0.000143	CcSEcCtD
Nilotinib—Paraesthesia—Pregabalin—epilepsy syndrome	1.76e-05	0.000143	CcSEcCtD
Nilotinib—Thrombocytopenia—Gabapentin—epilepsy syndrome	1.75e-05	0.000143	CcSEcCtD
Nilotinib—Nausea—Phenytoin—epilepsy syndrome	1.75e-05	0.000143	CcSEcCtD
Nilotinib—Tachycardia—Gabapentin—epilepsy syndrome	1.75e-05	0.000142	CcSEcCtD
Nilotinib—Dyspnoea—Pregabalin—epilepsy syndrome	1.74e-05	0.000142	CcSEcCtD
Nilotinib—Nausea—Oxcarbazepine—epilepsy syndrome	1.74e-05	0.000142	CcSEcCtD
Nilotinib—Vision blurred—Topiramate—epilepsy syndrome	1.74e-05	0.000142	CcSEcCtD
Nilotinib—Skin disorder—Gabapentin—epilepsy syndrome	1.74e-05	0.000142	CcSEcCtD
Nilotinib—Hyperhidrosis—Gabapentin—epilepsy syndrome	1.73e-05	0.000141	CcSEcCtD
Nilotinib—Tremor—Topiramate—epilepsy syndrome	1.73e-05	0.000141	CcSEcCtD
Nilotinib—Vomiting—Lamotrigine—epilepsy syndrome	1.73e-05	0.000141	CcSEcCtD
Nilotinib—Urticaria—Valproic Acid—epilepsy syndrome	1.72e-05	0.00014	CcSEcCtD
Nilotinib—Rash—Lamotrigine—epilepsy syndrome	1.72e-05	0.00014	CcSEcCtD
Nilotinib—Ill-defined disorder—Topiramate—epilepsy syndrome	1.71e-05	0.00014	CcSEcCtD
Nilotinib—Dermatitis—Lamotrigine—epilepsy syndrome	1.71e-05	0.00014	CcSEcCtD
Nilotinib—Body temperature increased—Valproic Acid—epilepsy syndrome	1.71e-05	0.000139	CcSEcCtD
Nilotinib—Abdominal pain—Valproic Acid—epilepsy syndrome	1.71e-05	0.000139	CcSEcCtD
Nilotinib—Anorexia—Gabapentin—epilepsy syndrome	1.71e-05	0.000139	CcSEcCtD
Nilotinib—Anaemia—Topiramate—epilepsy syndrome	1.71e-05	0.000139	CcSEcCtD
Nilotinib—Headache—Lamotrigine—epilepsy syndrome	1.7e-05	0.000139	CcSEcCtD
Nilotinib—Decreased appetite—Pregabalin—epilepsy syndrome	1.7e-05	0.000138	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	1.69e-05	0.000137	CcSEcCtD
Nilotinib—Fatigue—Pregabalin—epilepsy syndrome	1.69e-05	0.000137	CcSEcCtD
Nilotinib—Hypotension—Gabapentin—epilepsy syndrome	1.67e-05	0.000136	CcSEcCtD
Nilotinib—Nausea—Carbamazepine—epilepsy syndrome	1.67e-05	0.000136	CcSEcCtD
Nilotinib—Pain—Pregabalin—epilepsy syndrome	1.67e-05	0.000136	CcSEcCtD
Nilotinib—Constipation—Pregabalin—epilepsy syndrome	1.67e-05	0.000136	CcSEcCtD
Nilotinib—Malaise—Topiramate—epilepsy syndrome	1.67e-05	0.000136	CcSEcCtD
Nilotinib—Vertigo—Topiramate—epilepsy syndrome	1.66e-05	0.000135	CcSEcCtD
Nilotinib—Syncope—Topiramate—epilepsy syndrome	1.66e-05	0.000135	CcSEcCtD
Nilotinib—Leukopenia—Topiramate—epilepsy syndrome	1.65e-05	0.000135	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Gabapentin—epilepsy syndrome	1.63e-05	0.000133	CcSEcCtD
Nilotinib—Palpitations—Topiramate—epilepsy syndrome	1.63e-05	0.000133	CcSEcCtD
Nilotinib—Loss of consciousness—Topiramate—epilepsy syndrome	1.62e-05	0.000132	CcSEcCtD
Nilotinib—Insomnia—Gabapentin—epilepsy syndrome	1.62e-05	0.000132	CcSEcCtD
Nilotinib—Nausea—Lamotrigine—epilepsy syndrome	1.62e-05	0.000132	CcSEcCtD
Nilotinib—Cough—Topiramate—epilepsy syndrome	1.61e-05	0.000131	CcSEcCtD
Nilotinib—Feeling abnormal—Pregabalin—epilepsy syndrome	1.61e-05	0.000131	CcSEcCtD
Nilotinib—Paraesthesia—Gabapentin—epilepsy syndrome	1.61e-05	0.000131	CcSEcCtD
Nilotinib—Gastrointestinal pain—Pregabalin—epilepsy syndrome	1.6e-05	0.00013	CcSEcCtD
Nilotinib—Dyspnoea—Gabapentin—epilepsy syndrome	1.6e-05	0.00013	CcSEcCtD
Nilotinib—Hypertension—Topiramate—epilepsy syndrome	1.6e-05	0.00013	CcSEcCtD
Nilotinib—Hypersensitivity—Valproic Acid—epilepsy syndrome	1.59e-05	0.00013	CcSEcCtD
Nilotinib—Dyspepsia—Gabapentin—epilepsy syndrome	1.58e-05	0.000128	CcSEcCtD
Nilotinib—Chest pain—Topiramate—epilepsy syndrome	1.57e-05	0.000128	CcSEcCtD
Nilotinib—Myalgia—Topiramate—epilepsy syndrome	1.57e-05	0.000128	CcSEcCtD
Nilotinib—Arthralgia—Topiramate—epilepsy syndrome	1.57e-05	0.000128	CcSEcCtD
Nilotinib—Anxiety—Topiramate—epilepsy syndrome	1.57e-05	0.000128	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Topiramate—epilepsy syndrome	1.56e-05	0.000127	CcSEcCtD
Nilotinib—Decreased appetite—Gabapentin—epilepsy syndrome	1.56e-05	0.000127	CcSEcCtD
Nilotinib—Discomfort—Topiramate—epilepsy syndrome	1.55e-05	0.000127	CcSEcCtD
Nilotinib—Urticaria—Pregabalin—epilepsy syndrome	1.55e-05	0.000126	CcSEcCtD
Nilotinib—Asthenia—Valproic Acid—epilepsy syndrome	1.55e-05	0.000126	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	1.55e-05	0.000126	CcSEcCtD
Nilotinib—Fatigue—Gabapentin—epilepsy syndrome	1.55e-05	0.000126	CcSEcCtD
Nilotinib—Abdominal pain—Pregabalin—epilepsy syndrome	1.55e-05	0.000126	CcSEcCtD
Nilotinib—Body temperature increased—Pregabalin—epilepsy syndrome	1.55e-05	0.000126	CcSEcCtD
Nilotinib—Dry mouth—Topiramate—epilepsy syndrome	1.54e-05	0.000125	CcSEcCtD
Nilotinib—Pain—Gabapentin—epilepsy syndrome	1.53e-05	0.000125	CcSEcCtD
Nilotinib—Constipation—Gabapentin—epilepsy syndrome	1.53e-05	0.000125	CcSEcCtD
Nilotinib—Pruritus—Valproic Acid—epilepsy syndrome	1.53e-05	0.000125	CcSEcCtD
Nilotinib—Confusional state—Topiramate—epilepsy syndrome	1.52e-05	0.000124	CcSEcCtD
Nilotinib—Oedema—Topiramate—epilepsy syndrome	1.51e-05	0.000123	CcSEcCtD
Nilotinib—Infection—Topiramate—epilepsy syndrome	1.5e-05	0.000122	CcSEcCtD
Nilotinib—Shock—Topiramate—epilepsy syndrome	1.48e-05	0.000121	CcSEcCtD
Nilotinib—Diarrhoea—Valproic Acid—epilepsy syndrome	1.48e-05	0.00012	CcSEcCtD
Nilotinib—Nervous system disorder—Topiramate—epilepsy syndrome	1.48e-05	0.00012	CcSEcCtD
Nilotinib—Feeling abnormal—Gabapentin—epilepsy syndrome	1.48e-05	0.00012	CcSEcCtD
Nilotinib—Thrombocytopenia—Topiramate—epilepsy syndrome	1.48e-05	0.00012	CcSEcCtD
Nilotinib—Tachycardia—Topiramate—epilepsy syndrome	1.47e-05	0.00012	CcSEcCtD
Nilotinib—Gastrointestinal pain—Gabapentin—epilepsy syndrome	1.47e-05	0.000119	CcSEcCtD
Nilotinib—Skin disorder—Topiramate—epilepsy syndrome	1.46e-05	0.000119	CcSEcCtD
Nilotinib—Hyperhidrosis—Topiramate—epilepsy syndrome	1.46e-05	0.000119	CcSEcCtD
Nilotinib—Hypersensitivity—Pregabalin—epilepsy syndrome	1.44e-05	0.000117	CcSEcCtD
Nilotinib—Anorexia—Topiramate—epilepsy syndrome	1.44e-05	0.000117	CcSEcCtD
Nilotinib—Dizziness—Valproic Acid—epilepsy syndrome	1.43e-05	0.000116	CcSEcCtD
Nilotinib—Urticaria—Gabapentin—epilepsy syndrome	1.42e-05	0.000116	CcSEcCtD
Nilotinib—Body temperature increased—Gabapentin—epilepsy syndrome	1.42e-05	0.000115	CcSEcCtD
Nilotinib—Abdominal pain—Gabapentin—epilepsy syndrome	1.42e-05	0.000115	CcSEcCtD
Nilotinib—Hypotension—Topiramate—epilepsy syndrome	1.41e-05	0.000115	CcSEcCtD
Nilotinib—Asthenia—Pregabalin—epilepsy syndrome	1.4e-05	0.000114	CcSEcCtD
Nilotinib—Pruritus—Pregabalin—epilepsy syndrome	1.38e-05	0.000113	CcSEcCtD
Nilotinib—Vomiting—Valproic Acid—epilepsy syndrome	1.37e-05	0.000112	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Topiramate—epilepsy syndrome	1.37e-05	0.000112	CcSEcCtD
Nilotinib—Insomnia—Topiramate—epilepsy syndrome	1.36e-05	0.000111	CcSEcCtD
Nilotinib—Rash—Valproic Acid—epilepsy syndrome	1.36e-05	0.000111	CcSEcCtD
Nilotinib—Dermatitis—Valproic Acid—epilepsy syndrome	1.36e-05	0.000111	CcSEcCtD
Nilotinib—Headache—Valproic Acid—epilepsy syndrome	1.35e-05	0.00011	CcSEcCtD
Nilotinib—Paraesthesia—Topiramate—epilepsy syndrome	1.35e-05	0.00011	CcSEcCtD
Nilotinib—Dyspnoea—Topiramate—epilepsy syndrome	1.34e-05	0.000109	CcSEcCtD
Nilotinib—Diarrhoea—Pregabalin—epilepsy syndrome	1.34e-05	0.000109	CcSEcCtD
Nilotinib—Dyspepsia—Topiramate—epilepsy syndrome	1.33e-05	0.000108	CcSEcCtD
Nilotinib—Hypersensitivity—Gabapentin—epilepsy syndrome	1.32e-05	0.000108	CcSEcCtD
Nilotinib—Decreased appetite—Topiramate—epilepsy syndrome	1.31e-05	0.000107	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Topiramate—epilepsy syndrome	1.3e-05	0.000106	CcSEcCtD
Nilotinib—Fatigue—Topiramate—epilepsy syndrome	1.3e-05	0.000106	CcSEcCtD
Nilotinib—Dizziness—Pregabalin—epilepsy syndrome	1.29e-05	0.000105	CcSEcCtD
Nilotinib—Pain—Topiramate—epilepsy syndrome	1.29e-05	0.000105	CcSEcCtD
Nilotinib—Constipation—Topiramate—epilepsy syndrome	1.29e-05	0.000105	CcSEcCtD
Nilotinib—Asthenia—Gabapentin—epilepsy syndrome	1.29e-05	0.000105	CcSEcCtD
Nilotinib—Nausea—Valproic Acid—epilepsy syndrome	1.28e-05	0.000105	CcSEcCtD
Nilotinib—Pruritus—Gabapentin—epilepsy syndrome	1.27e-05	0.000103	CcSEcCtD
Nilotinib—Vomiting—Pregabalin—epilepsy syndrome	1.24e-05	0.000101	CcSEcCtD
Nilotinib—Feeling abnormal—Topiramate—epilepsy syndrome	1.24e-05	0.000101	CcSEcCtD
Nilotinib—Gastrointestinal pain—Topiramate—epilepsy syndrome	1.23e-05	0.0001	CcSEcCtD
Nilotinib—Rash—Pregabalin—epilepsy syndrome	1.23e-05	0.0001	CcSEcCtD
Nilotinib—Dermatitis—Pregabalin—epilepsy syndrome	1.23e-05	0.0001	CcSEcCtD
Nilotinib—Diarrhoea—Gabapentin—epilepsy syndrome	1.23e-05	9.99e-05	CcSEcCtD
Nilotinib—Headache—Pregabalin—epilepsy syndrome	1.22e-05	9.97e-05	CcSEcCtD
Nilotinib—Urticaria—Topiramate—epilepsy syndrome	1.2e-05	9.75e-05	CcSEcCtD
Nilotinib—Abdominal pain—Topiramate—epilepsy syndrome	1.19e-05	9.71e-05	CcSEcCtD
Nilotinib—Body temperature increased—Topiramate—epilepsy syndrome	1.19e-05	9.71e-05	CcSEcCtD
Nilotinib—Dizziness—Gabapentin—epilepsy syndrome	1.19e-05	9.65e-05	CcSEcCtD
Nilotinib—Nausea—Pregabalin—epilepsy syndrome	1.16e-05	9.45e-05	CcSEcCtD
Nilotinib—Vomiting—Gabapentin—epilepsy syndrome	1.14e-05	9.28e-05	CcSEcCtD
Nilotinib—Rash—Gabapentin—epilepsy syndrome	1.13e-05	9.2e-05	CcSEcCtD
Nilotinib—Dermatitis—Gabapentin—epilepsy syndrome	1.13e-05	9.19e-05	CcSEcCtD
Nilotinib—Headache—Gabapentin—epilepsy syndrome	1.12e-05	9.14e-05	CcSEcCtD
Nilotinib—Hypersensitivity—Topiramate—epilepsy syndrome	1.11e-05	9.05e-05	CcSEcCtD
Nilotinib—Asthenia—Topiramate—epilepsy syndrome	1.08e-05	8.81e-05	CcSEcCtD
Nilotinib—Pruritus—Topiramate—epilepsy syndrome	1.07e-05	8.69e-05	CcSEcCtD
Nilotinib—Nausea—Gabapentin—epilepsy syndrome	1.06e-05	8.67e-05	CcSEcCtD
Nilotinib—Diarrhoea—Topiramate—epilepsy syndrome	1.03e-05	8.4e-05	CcSEcCtD
Nilotinib—Dizziness—Topiramate—epilepsy syndrome	9.97e-06	8.12e-05	CcSEcCtD
Nilotinib—Vomiting—Topiramate—epilepsy syndrome	9.59e-06	7.81e-05	CcSEcCtD
Nilotinib—Rash—Topiramate—epilepsy syndrome	9.51e-06	7.74e-05	CcSEcCtD
Nilotinib—Dermatitis—Topiramate—epilepsy syndrome	9.5e-06	7.73e-05	CcSEcCtD
Nilotinib—Headache—Topiramate—epilepsy syndrome	9.45e-06	7.69e-05	CcSEcCtD
Nilotinib—Nausea—Topiramate—epilepsy syndrome	8.96e-06	7.29e-05	CcSEcCtD
Nilotinib—MAPK14—Immune System—IL1B—epilepsy syndrome	5.43e-07	5.03e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—SLC2A1—epilepsy syndrome	5.43e-07	5.03e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—AKT1—epilepsy syndrome	5.43e-07	5.02e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CYP11A1—epilepsy syndrome	5.42e-07	5.01e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—KDR—epilepsy syndrome	5.4e-07	4.99e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—RELA—epilepsy syndrome	5.39e-07	4.99e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NGF—epilepsy syndrome	5.38e-07	4.98e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	5.38e-07	4.98e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PLCB1—epilepsy syndrome	5.37e-07	4.97e-06	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—SRC—epilepsy syndrome	5.37e-07	4.97e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—TH—epilepsy syndrome	5.36e-07	4.95e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MTOR—epilepsy syndrome	5.34e-07	4.94e-06	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—AKT1—epilepsy syndrome	5.32e-07	4.92e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—BCL2—epilepsy syndrome	5.32e-07	4.92e-06	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—AKT1—epilepsy syndrome	5.29e-07	4.9e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MTOR—epilepsy syndrome	5.29e-07	4.89e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—FGF2—epilepsy syndrome	5.29e-07	4.89e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—HMOX1—epilepsy syndrome	5.28e-07	4.88e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	5.27e-07	4.88e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—JUN—epilepsy syndrome	5.27e-07	4.87e-06	CbGpPWpGaD
Nilotinib—HCK—Disease—AKT1—epilepsy syndrome	5.26e-07	4.87e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCR5—epilepsy syndrome	5.24e-07	4.85e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CYP2D6—epilepsy syndrome	5.23e-07	4.84e-06	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—VEGFA—epilepsy syndrome	5.23e-07	4.84e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—SRC—epilepsy syndrome	5.22e-07	4.82e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—AKT1—epilepsy syndrome	5.22e-07	4.82e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—CAT—epilepsy syndrome	5.21e-07	4.82e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—RELA—epilepsy syndrome	5.2e-07	4.81e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PRKCB—epilepsy syndrome	5.2e-07	4.81e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL6ST—epilepsy syndrome	5.18e-07	4.79e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—FGF2—epilepsy syndrome	5.17e-07	4.78e-06	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—AKT1—epilepsy syndrome	5.16e-07	4.78e-06	CbGpPWpGaD
Nilotinib—BLK—Immune System—AKT1—epilepsy syndrome	5.16e-07	4.78e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—TXNRD1—epilepsy syndrome	5.16e-07	4.77e-06	CbGpPWpGaD
Nilotinib—FGR—Immune System—AKT1—epilepsy syndrome	5.15e-07	4.76e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—HTR2A—epilepsy syndrome	5.13e-07	4.74e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—SRC—epilepsy syndrome	5.11e-07	4.72e-06	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—AKT1—epilepsy syndrome	5.11e-07	4.72e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—POMC—epilepsy syndrome	5.1e-07	4.72e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—MTOR—epilepsy syndrome	5.1e-07	4.71e-06	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—ALB—epilepsy syndrome	5.1e-07	4.71e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—SRC—epilepsy syndrome	5.09e-07	4.71e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—ABCB1—epilepsy syndrome	5.07e-07	4.69e-06	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—AKT1—epilepsy syndrome	5.04e-07	4.66e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—FGF2—epilepsy syndrome	5.01e-07	4.63e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—AQP1—epilepsy syndrome	5e-07	4.63e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—POMC—epilepsy syndrome	4.99e-07	4.62e-06	CbGpPWpGaD
Nilotinib—ABCB1—Transmembrane transport of small molecules—ALB—epilepsy syndrome	4.99e-07	4.62e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CCL2—epilepsy syndrome	4.99e-07	4.62e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—SRC—epilepsy syndrome	4.98e-07	4.61e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ADRA2A—epilepsy syndrome	4.98e-07	4.61e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—VEGFA—epilepsy syndrome	4.97e-07	4.6e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—BCHE—epilepsy syndrome	4.96e-07	4.59e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—SRC—epilepsy syndrome	4.96e-07	4.59e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CASP3—epilepsy syndrome	4.91e-07	4.54e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—RELA—epilepsy syndrome	4.91e-07	4.54e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	4.9e-07	4.54e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CYP2D6—epilepsy syndrome	4.89e-07	4.52e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CCL2—epilepsy syndrome	4.89e-07	4.52e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TSC2—epilepsy syndrome	4.87e-07	4.5e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CASP3—epilepsy syndrome	4.87e-07	4.5e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—AGT—epilepsy syndrome	4.86e-07	4.5e-06	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—AKT1—epilepsy syndrome	4.84e-07	4.48e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MTOR—epilepsy syndrome	4.82e-07	4.45e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—JUN—epilepsy syndrome	4.77e-07	4.41e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—APOE—epilepsy syndrome	4.77e-07	4.41e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—POMC—epilepsy syndrome	4.74e-07	4.39e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—POMC—epilepsy syndrome	4.73e-07	4.38e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—SLC2A1—epilepsy syndrome	4.73e-07	4.38e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—JUN—epilepsy syndrome	4.73e-07	4.37e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—SRC—epilepsy syndrome	4.72e-07	4.37e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—GPX1—epilepsy syndrome	4.71e-07	4.36e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—MTOR—epilepsy syndrome	4.71e-07	4.35e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—SRC—epilepsy syndrome	4.7e-07	4.35e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL1B—epilepsy syndrome	4.7e-07	4.35e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ADRA2A—epilepsy syndrome	4.7e-07	4.34e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PLCB1—epilepsy syndrome	4.68e-07	4.33e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—BCHE—epilepsy syndrome	4.68e-07	4.32e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—KDR—epilepsy syndrome	4.67e-07	4.32e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—TH—epilepsy syndrome	4.67e-07	4.32e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—PTGS2—epilepsy syndrome	4.66e-07	4.31e-06	CbGpPWpGaD
Nilotinib—CA4—Metabolism—AKT1—epilepsy syndrome	4.66e-07	4.31e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ADRA2A—epilepsy syndrome	4.66e-07	4.31e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—RELA—epilepsy syndrome	4.65e-07	4.3e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MMP9—epilepsy syndrome	4.64e-07	4.29e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—BCHE—epilepsy syndrome	4.64e-07	4.29e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CCL2—epilepsy syndrome	4.63e-07	4.29e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MMP9—epilepsy syndrome	4.6e-07	4.25e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MTOR—epilepsy syndrome	4.56e-07	4.22e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—JUN—epilepsy syndrome	4.55e-07	4.21e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CHRM3—epilepsy syndrome	4.53e-07	4.19e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—KCNJ11—epilepsy syndrome	4.53e-07	4.19e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—FGF2—epilepsy syndrome	4.51e-07	4.17e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PRKCB—epilepsy syndrome	4.49e-07	4.16e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL6ST—epilepsy syndrome	4.48e-07	4.14e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—HMOX1—epilepsy syndrome	4.47e-07	4.13e-06	CbGpPWpGaD
Nilotinib—CA2—Metabolism—AKT1—epilepsy syndrome	4.46e-07	4.13e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—SLC2A1—epilepsy syndrome	4.46e-07	4.13e-06	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PTGS2—epilepsy syndrome	4.46e-07	4.12e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CASP3—epilepsy syndrome	4.43e-07	4.1e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—SLC2A1—epilepsy syndrome	4.42e-07	4.09e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—FGF2—epilepsy syndrome	4.42e-07	4.09e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PLCB1—epilepsy syndrome	4.41e-07	4.08e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CAT—epilepsy syndrome	4.41e-07	4.08e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—TH—epilepsy syndrome	4.4e-07	4.07e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PLCB1—epilepsy syndrome	4.37e-07	4.05e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—TH—epilepsy syndrome	4.36e-07	4.03e-06	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—AKT1—epilepsy syndrome	4.36e-07	4.03e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—ALB—epilepsy syndrome	4.32e-07	4e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—JUN—epilepsy syndrome	4.3e-07	3.98e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	4.29e-07	3.97e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ABCB1—epilepsy syndrome	4.29e-07	3.97e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—SRC—epilepsy syndrome	4.28e-07	3.96e-06	CbGpPWpGaD
Nilotinib—CA1—Metabolism—AKT1—epilepsy syndrome	4.28e-07	3.96e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—SRC—epilepsy syndrome	4.24e-07	3.92e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CASP3—epilepsy syndrome	4.19e-07	3.88e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—RELA—epilepsy syndrome	4.19e-07	3.87e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—FGF2—epilepsy syndrome	4.19e-07	3.87e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MMP9—epilepsy syndrome	4.19e-07	3.87e-06	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—AKT1—epilepsy syndrome	4.19e-07	3.87e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—VEGFA—epilepsy syndrome	4.17e-07	3.86e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—AGT—epilepsy syndrome	4.13e-07	3.82e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—VEGFA—epilepsy syndrome	4.13e-07	3.82e-06	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—AKT1—epilepsy syndrome	4.11e-07	3.8e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MTOR—epilepsy syndrome	4.11e-07	3.8e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—RELA—epilepsy syndrome	4.1e-07	3.79e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—POMC—epilepsy syndrome	4.09e-07	3.79e-06	CbGpPWpGaD
Nilotinib—MAPK11—Gene Expression—AKT1—epilepsy syndrome	4.09e-07	3.78e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—SRC—epilepsy syndrome	4.08e-07	3.78e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—JUN—epilepsy syndrome	4.07e-07	3.77e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—APOE—epilepsy syndrome	4.05e-07	3.74e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MTOR—epilepsy syndrome	4.02e-07	3.72e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCL2—epilepsy syndrome	4.01e-07	3.71e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—GPX1—epilepsy syndrome	3.99e-07	3.69e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MMP9—epilepsy syndrome	3.96e-07	3.66e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—HMOX1—epilepsy syndrome	3.89e-07	3.6e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—RELA—epilepsy syndrome	3.89e-07	3.6e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—SRC—epilepsy syndrome	3.86e-07	3.57e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CAT—epilepsy syndrome	3.84e-07	3.55e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MTOR—epilepsy syndrome	3.81e-07	3.53e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PTGS2—epilepsy syndrome	3.78e-07	3.5e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CASP3—epilepsy syndrome	3.78e-07	3.49e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—SRC—epilepsy syndrome	3.77e-07	3.49e-06	CbGpPWpGaD
Nilotinib—BRAF—Disease—AKT1—epilepsy syndrome	3.76e-07	3.48e-06	CbGpPWpGaD
Nilotinib—CA9—Metabolism—AKT1—epilepsy syndrome	3.76e-07	3.48e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—VEGFA—epilepsy syndrome	3.76e-07	3.48e-06	CbGpPWpGaD
Nilotinib—KIT—Immune System—AKT1—epilepsy syndrome	3.71e-07	3.43e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CASP3—epilepsy syndrome	3.7e-07	3.42e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ABCG2—epilepsy syndrome	3.69e-07	3.41e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—HMOX1—epilepsy syndrome	3.67e-07	3.39e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—JUN—epilepsy syndrome	3.67e-07	3.39e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—SRC—epilepsy syndrome	3.65e-07	3.38e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—HMOX1—epilepsy syndrome	3.64e-07	3.36e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CAT—epilepsy syndrome	3.62e-07	3.35e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—FGF2—epilepsy syndrome	3.62e-07	3.35e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP2C19—epilepsy syndrome	3.6e-07	3.33e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—JUN—epilepsy syndrome	3.59e-07	3.32e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CAT—epilepsy syndrome	3.59e-07	3.32e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP11A1—epilepsy syndrome	3.57e-07	3.3e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MMP9—epilepsy syndrome	3.57e-07	3.3e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—VEGFA—epilepsy syndrome	3.56e-07	3.29e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ABCB1—epilepsy syndrome	3.52e-07	3.26e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—AKT1—epilepsy syndrome	3.51e-07	3.25e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CASP3—epilepsy syndrome	3.51e-07	3.24e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—AGT—epilepsy syndrome	3.5e-07	3.23e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MMP9—epilepsy syndrome	3.49e-07	3.23e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ABCB1—epilepsy syndrome	3.49e-07	3.23e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—POMC—epilepsy syndrome	3.48e-07	3.22e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GPX1—epilepsy syndrome	3.47e-07	3.21e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—APOE—epilepsy syndrome	3.43e-07	3.17e-06	CbGpPWpGaD
Nilotinib—KIT—Disease—AKT1—epilepsy syndrome	3.42e-07	3.17e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—JUN—epilepsy syndrome	3.41e-07	3.15e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—RELA—epilepsy syndrome	3.36e-07	3.11e-06	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—AKT1—epilepsy syndrome	3.34e-07	3.09e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MMP9—epilepsy syndrome	3.31e-07	3.06e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MTOR—epilepsy syndrome	3.3e-07	3.05e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—SRC—epilepsy syndrome	3.29e-07	3.04e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GPX1—epilepsy syndrome	3.27e-07	3.03e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GPX1—epilepsy syndrome	3.25e-07	3e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—AKT1—epilepsy syndrome	3.24e-07	3e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP2D6—epilepsy syndrome	3.22e-07	2.98e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—SRC—epilepsy syndrome	3.22e-07	2.98e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—VEGFA—epilepsy syndrome	3.21e-07	2.96e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—AKT1—epilepsy syndrome	3.17e-07	2.94e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—ALB—epilepsy syndrome	3.17e-07	2.93e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—AKT1—epilepsy syndrome	3.16e-07	2.93e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—VEGFA—epilepsy syndrome	3.14e-07	2.9e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—AKT1—epilepsy syndrome	3.1e-07	2.86e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—AKT1—epilepsy syndrome	3.08e-07	2.85e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ADRA2A—epilepsy syndrome	3.07e-07	2.84e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—BCHE—epilepsy syndrome	3.06e-07	2.83e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—SRC—epilepsy syndrome	3.05e-07	2.83e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—AGT—epilepsy syndrome	3.05e-07	2.82e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CASP3—epilepsy syndrome	3.03e-07	2.8e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—APOE—epilepsy syndrome	2.99e-07	2.76e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—VEGFA—epilepsy syndrome	2.97e-07	2.75e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—JUN—epilepsy syndrome	2.94e-07	2.72e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—POMC—epilepsy syndrome	2.94e-07	2.72e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—AKT1—epilepsy syndrome	2.94e-07	2.72e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—AKT1—epilepsy syndrome	2.92e-07	2.7e-06	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—AKT1—epilepsy syndrome	2.92e-07	2.7e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SLC2A1—epilepsy syndrome	2.92e-07	2.7e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PLCB1—epilepsy syndrome	2.88e-07	2.67e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—TH—epilepsy syndrome	2.87e-07	2.66e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—AGT—epilepsy syndrome	2.87e-07	2.66e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MMP9—epilepsy syndrome	2.86e-07	2.65e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—AGT—epilepsy syndrome	2.85e-07	2.63e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—APOE—epilepsy syndrome	2.81e-07	2.6e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—APOE—epilepsy syndrome	2.79e-07	2.58e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PTGS2—epilepsy syndrome	2.77e-07	2.57e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ALB—epilepsy syndrome	2.68e-07	2.48e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—AKT1—epilepsy syndrome	2.66e-07	2.46e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—SRC—epilepsy syndrome	2.64e-07	2.44e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—AKT1—epilepsy syndrome	2.63e-07	2.44e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—VEGFA—epilepsy syndrome	2.57e-07	2.38e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—POMC—epilepsy syndrome	2.56e-07	2.37e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—AKT1—epilepsy syndrome	2.54e-07	2.35e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—POMC—epilepsy syndrome	2.42e-07	2.24e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—HMOX1—epilepsy syndrome	2.4e-07	2.22e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—AKT1—epilepsy syndrome	2.4e-07	2.22e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—POMC—epilepsy syndrome	2.4e-07	2.22e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CAT—epilepsy syndrome	2.37e-07	2.19e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTGS2—epilepsy syndrome	2.35e-07	2.17e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—AKT1—epilepsy syndrome	2.34e-07	2.17e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ALB—epilepsy syndrome	2.34e-07	2.16e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ABCB1—epilepsy syndrome	2.3e-07	2.13e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—AKT1—epilepsy syndrome	2.27e-07	2.1e-06	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—AKT1—epilepsy syndrome	2.24e-07	2.07e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ALB—epilepsy syndrome	2.2e-07	2.04e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ALB—epilepsy syndrome	2.18e-07	2.02e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GPX1—epilepsy syndrome	2.14e-07	1.98e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTGS2—epilepsy syndrome	2.05e-07	1.89e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—AKT1—epilepsy syndrome	2.05e-07	1.89e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—AKT1—epilepsy syndrome	2e-07	1.85e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTGS2—epilepsy syndrome	1.93e-07	1.78e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTGS2—epilepsy syndrome	1.91e-07	1.77e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—AKT1—epilepsy syndrome	1.9e-07	1.76e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—AKT1—epilepsy syndrome	1.9e-07	1.76e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—AGT—epilepsy syndrome	1.88e-07	1.74e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—APOE—epilepsy syndrome	1.84e-07	1.7e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—AKT1—epilepsy syndrome	1.64e-07	1.52e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—POMC—epilepsy syndrome	1.58e-07	1.46e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ALB—epilepsy syndrome	1.44e-07	1.33e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—AKT1—epilepsy syndrome	1.39e-07	1.29e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTGS2—epilepsy syndrome	1.26e-07	1.17e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—AKT1—epilepsy syndrome	1.18e-07	1.09e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—AKT1—epilepsy syndrome	1.03e-07	9.51e-07	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—AKT1—epilepsy syndrome	9.69e-08	8.96e-07	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—AKT1—epilepsy syndrome	9.6e-08	8.88e-07	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—AKT1—epilepsy syndrome	6.33e-08	5.86e-07	CbGpPWpGaD
